Deepnoid Signs MOU with KMI Korea Medical Institute

Deepnoid, a first-generation domestic medical AI specialist company, announced on May 15 that it had signed a memorandum of understanding (MOU) with KMI Korea Medical Institute on May 9 for research on AI monitoring of health screening result assessments, and plans to actively expand its business into the health screening market.

Through this agreement, the two parties plan to collaborate on: ▲ research projects for LLM (Large Language Model)-based examination systems; ▲ improving the accuracy of screening result record reviews (screening) using generative AI technology; and ▲ joint research and commercialization in the field of medical imaging technology.

By combining KMI Korea Medical Institute's extensive health screening data with Deepnoid's generative AI technology, they aim to provide customized health screening services. Deepnoid will implement an LLM-based AI system to periodically automate and streamline the review of health screening data.

KMI Korea Medical Institute plans to support rapid and accurate clinical decision-making by medical professionals based on refined data. In addition, by providing screening results in a timely manner, the satisfaction of examinees and the efficiency of screening services are expected to improve. The system is also easily expandable to other medical information platforms, which is expected to help establish a foundation for the overall precision of medical data.

The agreement is expected to expand the scope of medical AI applications from lesion interpretation to everyday health management and screening data processing, thereby contributing to the broader adoption of medical AI services.

Lee Kwangbae, Chairman of KMI Korea Medical Institute, stated, "Through this agreement, we expect to enhance the value of the screening data KMI has accumulated over the past 40 years and strengthen the effectiveness of health screening services by utilizing generative AI technology."

Choi Woosik, CEO of Deepnoid, said, "The combination of KMI's accumulated medical expertise and data with our AI technology will create powerful synergy," adding, "We hope this agreement will serve as a turning point for expanding the scope of medical AI applications into everyday health management."

KMI Korea Medical Institute, established in 1985, is a health screening organization currently operating health screening centers in eight locations nationwide: three in Seoul (Gwanghwamun, Yeouido, Gangnam) and five in other regions (Suwon, Daegu, Busan, Gwangju, Jeju). In addition to activities for early disease detection, prevention, and public health promotion, it also engages in various social contribution projects.

Deepnoid is a leading domestic medical AI company that researches and develops disease imaging analysis solutions, including diagnosis and treatment guidance for cerebral aneurysms and lung diseases. Its main medical AI solutions include 'DEEP:NEURO,' which was temporarily listed as a non-reimbursable item under the national health insurance last year; 'M4CXR,' a generative AI-based chest X-ray interpretation report generation solution; and 'DEEP:CHEST,' a real-time multi-lung disease detection and diagnostic support solution.